HIV Infection Clinical Trial
Official title:
The Pharmacokinetics of Depot Medroxyprogesterone Acetate (DMPA) in the Absence and Presence of Lopinavir/Ritonavir in HIV-1 Infected Women
DMPA (depot medroxyprogesterone acetate or the 'depot' injection) is a widely used
contraception. It is popular in woman with HIV as it probably still works when you take HIV
drugs. HIV drugs can increase or decrease the level of other drugs (e.g. contraceptives) in
your bloodstream which may make them work less well or increase side effects. It is assumed
that DMPA can be given with HIV drugs there are no studies proving this.
The purpose of the study is to investigate whether an HIV drug combination containing
lopinavir/ritonavir affects DMPA when they are taken at the same time.
Status | Withdrawn |
Enrollment | 10 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements. 2. Non-pregnant, non-lactating premenopausal females. 3. No current hormonal contraception (short acting methods eg oral contraceptive pills and patches can be removed at screening) 4. Regular menstrual periods such that DMPA can be administered between days 1-5 of menstrual cycle 5. Between 18 and 45 years, inclusive. 6. Documented HIV-1 infection 7. Must be willing to use a barrier method of contraception to avoid pregnancy throughout the study, and for at least 56 days following completion of the study. 8. CD4 count > 200 at screening (Note: retesting of screening CD4 count allowed). 9. Clinician and patient happy to delay HAART until week 12 of study 10. Not currently on HAART and eligible to receive LPV/r and Truvada as determined by their primary HIV care provider in accordance with treatment guidelines 11. If history of HAART exposure, no virological failure (prior drug switches allowed if for tolerability/toxicity/convenience of dosing). 12. Agrees not to change regimen, outside the study recommendations, from baseline until end of the treatment period unless this is medically indicated as decided by the treating physician Exclusion Criteria: 1. Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic disorders or malignancy. 2. Have a body mass index (BMI) >35 3. Personal history of venous thromboembolism (VTE) or pulmonary embolism (PE) 4. Presence of any current active AIDS defining illness (Category C conditions in the CDC Classification System for HIV 1993) except stable cutaneous Kaposi's Sarcoma 5. Osteoporosis or significant risk factors for osteoporosis (alcohol abuse, long-term anticonvulsants/corticosteroids, BMI less than 18, eating disorder, previous low trauma fracture, significant family history osteoporosis) 6. Conditions for which DMPA is contra-indicated or risks outweigh benefits: 1. Significant multiple risk factors for arterial cardiovascular disease 2. Vascular disease 3. Previous or current venous thromboembolism (VTE) or pulmonary embolism (PE) 4. Ischaemic heart disease 5. Stroke (history of cerebrovascular accident) 6. Headaches migraine with aura, at any age 7. Unexplained vaginal bleeding 8. Gestational trophoblastic neoplasia (GTN) (includes hydatidiform mole, invasive mole, placental site trophoblastic tumour) hCG abnormal 9. Breast cancer (past or current) or strong family history 10. Diabetes nephropathy/retinopathy/neuropathy 11. Other vascular disease or diabetes of >20 years' duration 12. Viral hepatitis (active) 13. Presence or history of any sever hepatic disease where liver function tests have not returned to normal 14. Cirrhosis (decompensated) 7. Clinically relevant alcohol or drug use (positive urine drug screen, excluding cannabinoids) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study. 8. The use of disallowed concomitant therapy (See section 5.2). 9. Previous allergy to any of the constituents of the study pharmaceuticals. 10. Exposure to any investigational drug or placebo within 4 weeks of baseline. 11. Any HAART exposure within 6 months of screening for this study (ie participants need to be treatment-naïve or on a treatment interruption for 6 months or more). |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United Kingdom | St Stephen's Centre | London |
Lead Sponsor | Collaborator |
---|---|
St Stephens Aids Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pharmacokinetics of depot medroxyprogesterone acetate (DMPA) | To investigate the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) in the absence and presence of lopinavir/ritonavir in HIV- 1 infected women |
week 1 - week 24 | No |
Secondary | Impact of co-administration of DMPA and lopinavir/ritonavir | To investigate the impact of co-administration of DMPA and lopinavir/ritonavir on surrogate markers of contraceptive efficacy (LH, FSH, oestradiol) | Week 1 - week 24 | No |
Secondary | Safety of DMPA | To investigate the safety of DMPA in HIV infected women on lopinavir/ritonavir | Week 1 - week 24 | No |
Secondary | Impact of DMPA on lopinavir/ritonavir plasma concentrations | To investigate the impact of DMPA on lopinavir/ritonavir plasma concentrations compared with historical controls | week 1 - week 24 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |